As the global healthcare sector pivots toward advanced antimicrobial stewardship, a clear hierarchy of therapeutic options has emerged in 2026. Clinical data emphasizes a shift from broad-spectrum "one-size-fits-all" antibiotics to targeted molecular agents. The UTI Drugs Market forecast underscores this transition, highlighting how newer entries like Blujepa (gepotidacin) and Orlynvah...